IRS1 and type 2 diabetes mellitus: Oral administration of EnP at a dose of 75 mg/kg body weight reduced fasting blood glucose levels, improved oral glucose tolerance, alleviated insulin resistance, and mitigated hepatic insulin resistance by modulating the IRS1/PI3K and JNK signaling pathways in type 2 diabetic mice.